Naoko Takasu
Overview
Explore the profile of Naoko Takasu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
872
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hirayama M, Hatou S, Nomura M, Hokama R, Hirayama O, Inagaki E, et al.
Cell Rep Med
. 2025 Jan;
6(1):101847.
PMID: 39809262
A first-in-human investigator-initiated clinical study of a corneal endothelial cell substitute (CLS001) derived from a clinical-grade induced pluripotent stem cell (iPSC) line shows improvement of visual acuity and corneal stromal...
2.
Kunitomi A, Hirohata R, Osawa M, Washizu K, Arreola V, Saiki N, et al.
Stem Cell Reports
. 2024 May;
19(5):710-728.
PMID: 38701780
Heterogeneity among both primed and naive pluripotent stem cell lines remains a major unresolved problem. Here we show that expressing the maternal-specific linker histone H1FOO fused to a destabilizing domain...
3.
Kunitomi A, Hirohata R, Arreola V, Osawa M, Kato T, Nomura M, et al.
Cell Rep Methods
. 2022 Nov;
2(11):100317.
PMID: 36447645
Naive human induced pluripotent stem cells (iPSCs) can be generated by reprogramming somatic cells with Sendai virus (SeV) vectors. However, only dermal fibroblasts have been successfully reprogrammed this way, and...
4.
Yoshida S, Kato T, Sato Y, Umekage M, Ichisaka T, Tsukahara M, et al.
Med
. 2022 Nov;
4(1):51-66.e10.
PMID: 36395757
Background: Human induced pluripotent stem cells (iPSCs) are expected to be useful for regenerative medicine for many diseases. Many researchers have focused on and enabled the generation of differentiated cells...
5.
Kitano Y, Nishimura S, Kato T, Ueda A, Takigawa K, Umekage M, et al.
Mol Ther Methods Clin Dev
. 2022 Jun;
26:15-25.
PMID: 35755947
In order to expand the promise of regenerative medicine using allogeneic induced pluripotent stem cells (iPSCs), precise and efficient genome editing of human leukocyte antigen (HLA) genes would be advantageous...
6.
Yamamoto T, Sato Y, Yasuda S, Shikamura M, Tamura T, Takenaka C, et al.
Stem Cells Transl Med
. 2022 Apr;
11(5):527-538.
PMID: 35445254
Cell therapy using induced pluripotent stem cell (iPSC) derivatives may result in abnormal tissue generation because the cells undergo numerous cycles of mitosis before clinical application, potentially increasing the accumulation...
7.
Mizuno M, Endo K, Katano H, Amano N, Nomura M, Hasegawa Y, et al.
Stem Cells Transl Med
. 2021 Aug;
10(11):1530-1543.
PMID: 34342383
Mesenchymal stem cells (MSCs) can show trisomy 7; however, the safety of these cells has not been fully investigated. The purposes of this study were to determine the ratio of...
8.
Hanatani T, Takasu N
Stem Cell Res
. 2021 Jan;
50:102033.
PMID: 33445065
In Japan, induced pluripotent stem cell (iPSC) Stock Project has started from 2013. The goal of the Project is to manufacture and release clinical-grade HLA homozygous iPSC lines that can...
9.
Ueda T, Kumagai A, Iriguchi S, Yasui Y, Miyasaka T, Nakagoshi K, et al.
Cancer Sci
. 2020 Mar;
111(5):1478-1490.
PMID: 32133731
The use of allogeneic, pluripotent stem-cell-derived immune cells for cancer immunotherapy has been the subject of recent clinical trials. In Japan, investigator-initiated clinical trials will soon begin for ovarian cancer...
10.
Umekage M, Sato Y, Takasu N
Inflamm Regen
. 2019 Sep;
39:17.
PMID: 31497180
Induced pluripotent stem cells (iPSCs) can be produced from various somatic cells and have the ability to differentiate into various cells and tissues of the body. Regenerative medicine using iPSCs...